| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/13/2008 | CA2662998A1 Benzotriazole kinase modulators |
| 03/13/2008 | CA2662870A1 Therapeutic compounds for diseases and disorders |
| 03/13/2008 | CA2662852A1 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| 03/13/2008 | CA2662831A1 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-.alpha.-d-mannopyranosyl-oxy)-phenyl] hexane |
| 03/13/2008 | CA2662776A1 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 03/13/2008 | CA2662748A1 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| 03/13/2008 | CA2662732A1 Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections |
| 03/13/2008 | CA2662728A1 Substituted bipyridine derivatives and their use |
| 03/13/2008 | CA2662710A1 Oral polymeric membrane feruloyl esterase producing bacteria formulation |
| 03/13/2008 | CA2662705A1 Hypertension-ameliorating agent |
| 03/13/2008 | CA2662702A1 Difluorinated piperidines for treatment of alzheimer's disease and related conditions |
| 03/13/2008 | CA2662628A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| 03/13/2008 | CA2662626A1 Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 03/13/2008 | CA2662607A1 Composition comprising reduced coenzyme q10 and lysolecithin |
| 03/13/2008 | CA2662535A1 Method for reducing or alleviating inflammation in the digestive tract |
| 03/13/2008 | CA2662491A1 Combinations containing a 4-acylaminopyridine derivative |
| 03/13/2008 | CA2662435A1 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| 03/13/2008 | CA2662434A1 Topical compositions |
| 03/13/2008 | CA2662337A1 Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| 03/13/2008 | CA2662320A1 Bcl inhibitors treating platelet excess |
| 03/13/2008 | CA2662308A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 03/13/2008 | CA2662281A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as ep2 receptor modulators |
| 03/13/2008 | CA2662147A1 L-oddc prodrugs for cancer |
| 03/13/2008 | CA2662112A1 Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators |
| 03/13/2008 | CA2662091A1 N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| 03/13/2008 | CA2662084A1 Combination treatment for diabetes mellitus |
| 03/13/2008 | CA2662040A1 Pharmaceutical composition comprising candesartan cilexetil |
| 03/13/2008 | CA2662031A1 Heteroaryl derivatives as protein kinase inhibitors |
| 03/13/2008 | CA2661992A1 Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient |
| 03/13/2008 | CA2661975A1 Benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger |
| 03/13/2008 | CA2661830A1 Dry powder compound formulations and uses thereof |
| 03/13/2008 | CA2661404A1 Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| 03/13/2008 | CA2661315A1 Pyridin-3-yl derivatives as immunomodulating agents |
| 03/13/2008 | CA2661308A1 Neukinase, a downstream protein of neuregulin |
| 03/13/2008 | CA2661105A1 Pyridin-4-yl derivatives as immunomodulating agents |
| 03/13/2008 | CA2661102A1 Thiophene derivatives as s1p1/edg1 receptor agonists |
| 03/13/2008 | CA2660685A1 Aqueous formulation comprising an antitumor agent |
| 03/13/2008 | CA2659037A1 Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity |
| 03/13/2008 | CA2654283A1 Methods of diagnosing and treating complications of pregnancy |
| 03/13/2008 | CA2559634A1 Pharmaceutical preparations for the treatment of arthritis |
| 03/12/2008 | EP1897959A1 Target for therapy of cognitive impairment |
| 03/12/2008 | EP1897947A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897946A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897945A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897944A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897943A2 IL-17 homologous polypeptides and therapeutic uses thereof |
| 03/12/2008 | EP1897942A1 Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| 03/12/2008 | EP1897941A1 Means for increasing intracellular levels of protoporphyrin IX and use thereof |
| 03/12/2008 | EP1897900A1 Process for production of polymerized coordination compound of platinum complex |
| 03/12/2008 | EP1897883A2 Cationic porphyrin derivatives as antibacterial agents |
| 03/12/2008 | EP1897882A1 N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
| 03/12/2008 | EP1897881A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| 03/12/2008 | EP1897880A1 1,3-benzothiazinone derivative and use thereof |
| 03/12/2008 | EP1897879A2 2,4,5 substituted piperidines as renin inhibitors |
| 03/12/2008 | EP1897877A2 Process for producing crystal |
| 03/12/2008 | EP1897876A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| 03/12/2008 | EP1897872A1 Activator for peroxisome proliferator-activated receptor |
| 03/12/2008 | EP1897871A1 Benzenoid ansamycin derivative |
| 03/12/2008 | EP1897870A1 Pharmaceutical composition comprising 2-pyridone derivative as active ingredient |
| 03/12/2008 | EP1897867A1 Compounds, preparation process, and uses thereof used for interrupting reuptake of 5-hydroxytryptamine and norepinephrine or treating diseases such as depression et al. |
| 03/12/2008 | EP1897864A1 Anthracene derivatives and the use thereof for treating benign and malignant tumors |
| 03/12/2008 | EP1897560A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 03/12/2008 | EP1897559A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 03/12/2008 | EP1897558A1 Solid preparation |
| 03/12/2008 | EP1897552A1 Polymer-conjugated glycosylated neublastin |
| 03/12/2008 | EP1897551A1 Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage |
| 03/12/2008 | EP1897550A2 Prodrugs of Excitatory Amino Acids |
| 03/12/2008 | EP1897549A1 Radical scavenger and active oxygen eliminating agent |
| 03/12/2008 | EP1897548A1 T cell regulation |
| 03/12/2008 | EP1897547A1 Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications |
| 03/12/2008 | EP1897546A1 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| 03/12/2008 | EP1897545A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 03/12/2008 | EP1897544A1 Opioid agonist and antagonist combinations |
| 03/12/2008 | EP1897543A1 Buprenorphine- wafer for drug substitution therapy |
| 03/12/2008 | EP1897542A1 Aqueous formulation comprising an antitumor agent |
| 03/12/2008 | EP1897541A2 Hypoglycemic agent |
| 03/12/2008 | EP1897540A2 Inhibition of STAT3 signal transduction for human cancer therapy |
| 03/12/2008 | EP1897539A1 Anti-fatigue composition |
| 03/12/2008 | EP1897451A1 Tasteless nutritional supplement containing free amino acids |
| 03/12/2008 | EP1897450A1 Compound containing alpha lipoic acid |
| 03/12/2008 | EP1897441A1 TGF-alpha polypeptides, functional fragments and methods of use therefor |
| 03/12/2008 | EP1896600A2 Anti-cancer combination treatment and kit-of-part |
| 03/12/2008 | EP1896587A2 METHODS FOR PRODUCING MICRORNAs |
| 03/12/2008 | EP1896585A2 Double-stranded synthetic oligonucleotides useful for inducing apoptosis of osteoclasts for the treatment of osteopenic pathologies |
| 03/12/2008 | EP1896581A2 Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| 03/12/2008 | EP1896492A2 Platinum complexes with mononitrile-containing ligands |
| 03/12/2008 | EP1896491A2 Monoazole ligand platinum analogs |
| 03/12/2008 | EP1896489A1 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof |
| 03/12/2008 | EP1896487A1 Process for the preparation of sulfonic acid salts of oxabispidines |
| 03/12/2008 | EP1896485A1 Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors |
| 03/12/2008 | EP1896483A2 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| 03/12/2008 | EP1896480A1 Cripowellins and synthetic derivatives thereof used as medicaments |
| 03/12/2008 | EP1896479A1 Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists |
| 03/12/2008 | EP1896478A2 Aspartyl protease inhibitors |
| 03/12/2008 | EP1896477A1 Aspartyl protease inhibitors |
| 03/12/2008 | EP1896475A2 Process for the preparation of bicyclic compounds |
| 03/12/2008 | EP1896473A1 1- ( 2-amino-3- (substituted alkyl)-3h-benzimidazoiylmethyl) -3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus |
| 03/12/2008 | EP1896472A1 Alpha-carbolines as cdk-1 inhibitors |
| 03/12/2008 | EP1896471A1 Imidazopyridine derivatives as acid pump antagonists |
| 03/12/2008 | EP1896470A2 Pyrrolopyridine derivatives as protein kinase inhibitors |